Åsa Wallin
21 – 30 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts.
(
- Contribution to journal › Article
- 2014
-
Mark
Early- versus Late-onset Alzheimer’s Disease—3-year Outcomes of Cholinesterase Inhibitor Treatment in Routine Clinical Practice.
2014) 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
- 2013
-
Mark
Mild versus Moderate Stage of Alzheimer’s Disease—Three-year Outcomes of Cholinesterase Inhibitor Therapy in a Routine Clinical Setting.
(
- Contribution to conference › Abstract
-
Mark
Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
(
- Contribution to journal › Article
-
Mark
Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.
(
- Contribution to journal › Article
-
Mark
Living Alone in Alzheimer’s Disease—The Influence of Functional Impairment.
2013) 6th Clinical Trials Conference on Alzheimer’s Disease (CTAD)(
- Contribution to conference › Poster
-
Mark
Three-year outcome of rivastigmine treatment in Alzheimer's disease in a routine clinical setting.
2013) 11th International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PD 2013)(
- Contribution to conference › Poster
- 2012
-
Mark
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
(
- Contribution to journal › Article
-
Mark
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
(
- Contribution to journal › Article